Grufity logo
Grufity logo
EYEN

EYEN - Eyenovia Inc Stock Price, Fair Value and News

$3.49-0.10 (-2.79%)
Delayed as of 11 Sep 2026, 04:00 pm ET

EYEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EYEN Price Action

Last 7 days

5.8%

Last 30 days

29.7%

Last 90 days

28.3%

Trailing 12 Months

-70.9%

EYEN RSI Chart

EYEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EYEN Valuation

Market Cap

54.2M

Price/Earnings (Trailing)

8.15

Price/Sales (Trailing)

38.72

Price/Free Cashflow

-3.87

EYEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EYEN Fundamentals

EYEN Revenue

Revenue (TTM)

1.4M

EYEN Earnings

Earnings (TTM)

6.7M

Earnings Growth (Yr)

456.13%

Earnings Growth (Qtr)

250.1%

EYEN Profitability

Operating Margin

78.35%

Return on Equity

6.53%

Return on Assets

5.88%

Free Cashflow Yield

-25.83%

EYEN Investor Care

Shares Dilution (1Y)

220.08%

Diluted EPS (TTM)

-5.33

Revenue & Growth

How Eyenovia Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20261.0M1.4M--
202567.1K44.4K345.3K813.5K
20247.0M4.7M2.4M57.3K
2023--11.7M9.4M
20215.0M8.0M11.0M14.0M
2020---2.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Eyenovia Inc

EYEN
Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
 CEO
 WEBSITEeyenovia.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES41

Eyenovia Inc Frequently Asked Questions

EYEN is the stock ticker symbol of Eyenovia Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Sep 11 2026, market cap of Eyenovia Inc is 54.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Sep 11 2026, EYEN's PE ratio (Price to Earnings) is 8.15 and Price to Sales (PS) ratio is 38.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYEN PE ratio will change depending on the future growth rate expectations of investors.